These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Villanueva V; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López González FJ; Flores J; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A Epilepsy Res; 2014 Sep; 108(7):1243-52. PubMed ID: 24908564 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P; Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424 [TBL] [Abstract][Full Text] [Related]
4. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials. Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D; Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761 [TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Hufnagel A; Ben-Menachem E; Gabbai AA; Falcão A; Almeida L; Soares-da-Silva P Epilepsy Res; 2013 Feb; 103(2-3):262-9. PubMed ID: 22871333 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Gil-Nagel A; Elger C; Ben-Menachem E; Halász P; Lopes-Lima J; Gabbai AA; Nunes T; Falcão A; Almeida L; da-Silva PS Epilepsia; 2013 Jan; 54(1):98-107. PubMed ID: 22882018 [TBL] [Abstract][Full Text] [Related]
7. Clinical experience with eslicarbazepine acetate in adults with sub-analysis of elderly. Nielsen MK; Petrenaite V; Andersen NB Seizure; 2017 Dec; 53():94-99. PubMed ID: 29172139 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. Jacobson MP; Pazdera L; Bhatia P; Grinnell T; Cheng H; Blum D; BMC Neurol; 2015 Mar; 15():46. PubMed ID: 25880756 [TBL] [Abstract][Full Text] [Related]
9. [Exalief as a newer antiepileptic drug for adjunctive therapy of refractory partial-onset seizures]. Ermolenko NA; Buchneva IA Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):129-34. PubMed ID: 25629136 [TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study. Trinka E; Rocamora R; Chaves J; Moreira J; Ikedo F; Soares-da-Silva P; Epilepsia; 2020 Oct; 61(10):2129-2141. PubMed ID: 32944934 [TBL] [Abstract][Full Text] [Related]
11. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P Epilepsy Res; 2010 May; 89(2-3):278-85. PubMed ID: 20299189 [TBL] [Abstract][Full Text] [Related]
12. Eslicarbazepine acetate for partial-onset seizures. Rauchenzauner M; Luef G Expert Rev Neurother; 2011 Dec; 11(12):1673-81. PubMed ID: 22091592 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America. Sperling MR; Harvey J; Grinnell T; Cheng H; Blum D; Epilepsia; 2015 Apr; 56(4):546-55. PubMed ID: 25689448 [TBL] [Abstract][Full Text] [Related]
14. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P; Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898 [TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures. Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260 [TBL] [Abstract][Full Text] [Related]
16. Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures. Villanueva V; Holtkamp M; Delanty N; Rodriguez-Uranga J; McMurray R; Santagueda P J Neurol; 2017 Nov; 264(11):2232-2248. PubMed ID: 28921040 [TBL] [Abstract][Full Text] [Related]
17. Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy. Holtkamp M; McMurray R; Bagul M; Sousa R; Kockelmann E Acta Neurol Scand; 2016 Jul; 134(1):76-82. PubMed ID: 26915469 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study. Trinka E; Ben-Menachem E; Kowacs PA; Elger C; Keller B; Löffler K; Rocha JF; Soares-da-Silva P Epilepsia; 2018 Feb; 59(2):479-491. PubMed ID: 29369348 [TBL] [Abstract][Full Text] [Related]
19. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423 [TBL] [Abstract][Full Text] [Related]
20. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies. Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]